High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation

Koichi Miyamura, Takuya Yamashita, Yoshiko Atsuta, Tatsuo Ichinohe, Koji Kato, Naoyuki Uchida, Takahiro Fukuda, Kazuteru Ohashi, Hiroyasu Ogawa, Tetsuya Eto, Masami Inoue, Satoshi Takahashi, Takehiko Mori, Heiwa Kanamori, Hiromasa Yabe, Asahito Hama, Shinichiro Okamoto, Yoshihiro Inamoto

Research output: Contribution to journalArticle

Abstract

The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation (HCT) has been increasingly recognized for managing late effects such as subsequent cancers and cardiovascular events. A substantial population, however, has already terminated LTFU at HCT centers. To better characterize follow-up termination, we analyzed the Japanese transplant registry database. The study cohort included 17 980 survivors beyond 2 years who underwent their first allogeneic HCT between 1974 and 2013. The median patient age at HCT was 34 years (range, 0-76 years). Follow-up at their HCT center was terminated in 4987 patients. The cumulative incidence of follow-up termination was 28% (95% confidence interval [CI], 27%-29%) at 10 years, increasing to 67% (95% CI, 65%-69%) at 25 years after HCT. Pediatric patients showed the lowest probability of follow-up termination for up to 16 years after HCT, whereas adolescent and young adult (AYA) patients showed the highest probability of follow-up termination throughout the period. Follow-up termination was most often made by physicians based on the patient's good physical condition. Multivariate analysis identified 6 factors associated with follow-up termination: AYA patients, female patients, standard-risk malignancy or nonmalignant disease, unrelated bone marrow transplantation, HCT between 2000 and 2005, and absence of chronic graft-versus-host disease. These results suggest the need for education of both physicians and patients about the importance of LTFU, even in survivors with good physical condition. The decreased risk for follow-up termination after 2005 may suggest the increasing focus on LTFU in recent years.

Original languageEnglish
Pages (from-to)397-405
Number of pages9
JournalBlood advances
Volume3
Issue number3
DOIs
Publication statusPublished - Feb 12 2019

Fingerprint

Cell Transplantation
Survivors
Young Adult
Confidence Intervals
Physicians
Graft vs Host Disease
Bone Marrow Transplantation
Registries
Neoplasms
Cohort Studies
Multivariate Analysis
Databases
Pediatrics
Transplants
Education
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. / Miyamura, Koichi; Yamashita, Takuya; Atsuta, Yoshiko; Ichinohe, Tatsuo; Kato, Koji; Uchida, Naoyuki; Fukuda, Takahiro; Ohashi, Kazuteru; Ogawa, Hiroyasu; Eto, Tetsuya; Inoue, Masami; Takahashi, Satoshi; Mori, Takehiko; Kanamori, Heiwa; Yabe, Hiromasa; Hama, Asahito; Okamoto, Shinichiro; Inamoto, Yoshihiro.

In: Blood advances, Vol. 3, No. 3, 12.02.2019, p. 397-405.

Research output: Contribution to journalArticle

Miyamura, K, Yamashita, T, Atsuta, Y, Ichinohe, T, Kato, K, Uchida, N, Fukuda, T, Ohashi, K, Ogawa, H, Eto, T, Inoue, M, Takahashi, S, Mori, T, Kanamori, H, Yabe, H, Hama, A, Okamoto, S & Inamoto, Y 2019, 'High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation', Blood advances, vol. 3, no. 3, pp. 397-405. https://doi.org/10.1182/bloodadvances.2018026039
Miyamura, Koichi ; Yamashita, Takuya ; Atsuta, Yoshiko ; Ichinohe, Tatsuo ; Kato, Koji ; Uchida, Naoyuki ; Fukuda, Takahiro ; Ohashi, Kazuteru ; Ogawa, Hiroyasu ; Eto, Tetsuya ; Inoue, Masami ; Takahashi, Satoshi ; Mori, Takehiko ; Kanamori, Heiwa ; Yabe, Hiromasa ; Hama, Asahito ; Okamoto, Shinichiro ; Inamoto, Yoshihiro. / High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. In: Blood advances. 2019 ; Vol. 3, No. 3. pp. 397-405.
@article{491621268c974c089e356ab69c0909ca,
title = "High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation",
abstract = "The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation (HCT) has been increasingly recognized for managing late effects such as subsequent cancers and cardiovascular events. A substantial population, however, has already terminated LTFU at HCT centers. To better characterize follow-up termination, we analyzed the Japanese transplant registry database. The study cohort included 17 980 survivors beyond 2 years who underwent their first allogeneic HCT between 1974 and 2013. The median patient age at HCT was 34 years (range, 0-76 years). Follow-up at their HCT center was terminated in 4987 patients. The cumulative incidence of follow-up termination was 28{\%} (95{\%} confidence interval [CI], 27{\%}-29{\%}) at 10 years, increasing to 67{\%} (95{\%} CI, 65{\%}-69{\%}) at 25 years after HCT. Pediatric patients showed the lowest probability of follow-up termination for up to 16 years after HCT, whereas adolescent and young adult (AYA) patients showed the highest probability of follow-up termination throughout the period. Follow-up termination was most often made by physicians based on the patient's good physical condition. Multivariate analysis identified 6 factors associated with follow-up termination: AYA patients, female patients, standard-risk malignancy or nonmalignant disease, unrelated bone marrow transplantation, HCT between 2000 and 2005, and absence of chronic graft-versus-host disease. These results suggest the need for education of both physicians and patients about the importance of LTFU, even in survivors with good physical condition. The decreased risk for follow-up termination after 2005 may suggest the increasing focus on LTFU in recent years.",
author = "Koichi Miyamura and Takuya Yamashita and Yoshiko Atsuta and Tatsuo Ichinohe and Koji Kato and Naoyuki Uchida and Takahiro Fukuda and Kazuteru Ohashi and Hiroyasu Ogawa and Tetsuya Eto and Masami Inoue and Satoshi Takahashi and Takehiko Mori and Heiwa Kanamori and Hiromasa Yabe and Asahito Hama and Shinichiro Okamoto and Yoshihiro Inamoto",
year = "2019",
month = "2",
day = "12",
doi = "10.1182/bloodadvances.2018026039",
language = "English",
volume = "3",
pages = "397--405",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation

AU - Miyamura, Koichi

AU - Yamashita, Takuya

AU - Atsuta, Yoshiko

AU - Ichinohe, Tatsuo

AU - Kato, Koji

AU - Uchida, Naoyuki

AU - Fukuda, Takahiro

AU - Ohashi, Kazuteru

AU - Ogawa, Hiroyasu

AU - Eto, Tetsuya

AU - Inoue, Masami

AU - Takahashi, Satoshi

AU - Mori, Takehiko

AU - Kanamori, Heiwa

AU - Yabe, Hiromasa

AU - Hama, Asahito

AU - Okamoto, Shinichiro

AU - Inamoto, Yoshihiro

PY - 2019/2/12

Y1 - 2019/2/12

N2 - The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation (HCT) has been increasingly recognized for managing late effects such as subsequent cancers and cardiovascular events. A substantial population, however, has already terminated LTFU at HCT centers. To better characterize follow-up termination, we analyzed the Japanese transplant registry database. The study cohort included 17 980 survivors beyond 2 years who underwent their first allogeneic HCT between 1974 and 2013. The median patient age at HCT was 34 years (range, 0-76 years). Follow-up at their HCT center was terminated in 4987 patients. The cumulative incidence of follow-up termination was 28% (95% confidence interval [CI], 27%-29%) at 10 years, increasing to 67% (95% CI, 65%-69%) at 25 years after HCT. Pediatric patients showed the lowest probability of follow-up termination for up to 16 years after HCT, whereas adolescent and young adult (AYA) patients showed the highest probability of follow-up termination throughout the period. Follow-up termination was most often made by physicians based on the patient's good physical condition. Multivariate analysis identified 6 factors associated with follow-up termination: AYA patients, female patients, standard-risk malignancy or nonmalignant disease, unrelated bone marrow transplantation, HCT between 2000 and 2005, and absence of chronic graft-versus-host disease. These results suggest the need for education of both physicians and patients about the importance of LTFU, even in survivors with good physical condition. The decreased risk for follow-up termination after 2005 may suggest the increasing focus on LTFU in recent years.

AB - The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation (HCT) has been increasingly recognized for managing late effects such as subsequent cancers and cardiovascular events. A substantial population, however, has already terminated LTFU at HCT centers. To better characterize follow-up termination, we analyzed the Japanese transplant registry database. The study cohort included 17 980 survivors beyond 2 years who underwent their first allogeneic HCT between 1974 and 2013. The median patient age at HCT was 34 years (range, 0-76 years). Follow-up at their HCT center was terminated in 4987 patients. The cumulative incidence of follow-up termination was 28% (95% confidence interval [CI], 27%-29%) at 10 years, increasing to 67% (95% CI, 65%-69%) at 25 years after HCT. Pediatric patients showed the lowest probability of follow-up termination for up to 16 years after HCT, whereas adolescent and young adult (AYA) patients showed the highest probability of follow-up termination throughout the period. Follow-up termination was most often made by physicians based on the patient's good physical condition. Multivariate analysis identified 6 factors associated with follow-up termination: AYA patients, female patients, standard-risk malignancy or nonmalignant disease, unrelated bone marrow transplantation, HCT between 2000 and 2005, and absence of chronic graft-versus-host disease. These results suggest the need for education of both physicians and patients about the importance of LTFU, even in survivors with good physical condition. The decreased risk for follow-up termination after 2005 may suggest the increasing focus on LTFU in recent years.

UR - http://www.scopus.com/inward/record.url?scp=85061134713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061134713&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018026039

DO - 10.1182/bloodadvances.2018026039

M3 - Article

C2 - 30728138

AN - SCOPUS:85061134713

VL - 3

SP - 397

EP - 405

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 3

ER -